#USA #Los Angeles #Actinium Pharmaceuticals #SNMMI 2026 #CAR Optimization

Actinium Pharmaceuticals Presents Innovative Findings

On May 31, 2026, Actinium Pharmaceuticals, Inc. showcased significant advancements in radiochemistry at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting held in Los Angeles. The highlight of their presentation was the optimization of the chelator-to-antibody ratio (CAR), a pivotal design aspect that significantly enhances the efficacy of next-generation radioconjugates.

The optimized CAR results promise to improve tumor targeting and pharmacokinetics of Actinium-225 labeled antibodies. Notably, the findings indicated that lower CAR conjugates maintain effective tumor targeting while minimizing adverse uptake in healthy organs. Improved tuning of CAR not only supports enhanced drug delivery but also creates the opportunity for safer dosing protocols, maximizing therapeutic potential.

The Science Behind CAR Optimization

In their groundbreaking study, Actinium’s research team meticulously analyzed the relationship between the chelator-to-antibody ratio and the performance of radioconjugates. CAR directly impacts radiolabeling efficiency, antigen binding, internalization, and biodistribution. The research demonstrated that having an optimal balance in this ratio is crucial to ensure that the antibody carriers effectively deliver the radioactive payload to the tumors without adversely affecting healthy tissues.

Sandesh Seth, the company’s Chairman and CEO, stated, "Our CAR optimization data emphasize our extensive radiochemistry expertise and commitment to maximizing therapeutic windows. Achieving the right chelator-to-antibody ratio ensures the biological effectiveness of our antibody while allowing robust labeling with 225Ac and favorable pharmacokinetics. These advances have direct implications for the design and implementation of next-generation radioconjugates."

Key Findings from the Presentation

The poster titled 'Optimizing Chelator-to-Antibody Ratio Improves Tumor Targeting and Pharmacokinetics of 225Ac-Labeled Antibodies' included several vital discoveries:
1. Antibody-DOTA Conjugate Range: The study exhibited a range of CAR values, specifically ranging from 0.7 to 9. It was identified that a CAR of 1.7 or more enables substantial 225Ac labeling, while a CAR of 0.7 is inadequate for effective activity.
2. Antigen Binding Integrity: High levels of antigen binding were noted at lower CAR values (91-98% at CAR 0.7-3.2), whereas binding could degrade significantly at elevated CAR levels (79-85% at CAR 7-9). This indicates that excessive loading impacts the antibody's capability to infiltrate tumor cells efficiently.
3. In Vivo Performance: In animal models, both low and high CAR conjugates showed similar tumor uptake; however, the lower CAR conjugate led to significantly reduced accumulation in the liver and spleen, potentially allowing for a broader therapeutic index.
4. Stability Over Time: Both conjugates displayed excellent stability over a week, maintaining a radiochemical purity above 97%. This indicates that performance can be optimized without compromising manufacturability or clinical supply.

These findings significantly de-risk the broader pipeline of Actinium, enabling a more effective range of therapeutic options for cancer treatment through targeted radiotherapies.

Looking Forward

Actinium Pharmaceuticals remains dedicated to transforming cancer treatment through their innovative suite of radioconjugates, aiming for enhanced efficacy while minimizing side effects on healthy tissues. Their research and commitment are set to spearhead advancements in the fields of solid tumors and hematologic malignancies. By capitalizing on proprietary capabilities in radiochemistry, Actinium is paving the way for a future in which precision medicine becomes the standard in oncology.

For further information and updates on their research, please visit Actinium Pharmaceuticals.